





Barriers for recruitment Potential solutions Discussion about partnerships with patients • Ask simple questions to identify sero-different stable couples of your patients • Haveyou got an stable partner? • Is he/she HIV negative? • Does he/she routinely screen for HIV? • Give a very short introduction to the PARTNER study and refer to the research nurses/staff • If possible, integrate routine HIV testing to the HIV neg- partner of your patient • Clinics most successful in recruiting couples into the Partner study do so



PARTNE

Busy clinics Nurse collaboration

- The role of research nurses/staff is essential
- Clinics most successful in recruiting couples into the Partner study have dedicated staff
 - Information about the study
 - HIV samples
 - Questionnaires
 - Data management (e-CRF)
 - Follow-up schedules



Summary Barriers for recrutiment 1. Discussion about partnerships with patients 2. Discussion about condom use is in many cases obviated 3. Busy clinics don't have time enough to discuss the study with patients & couples Potential solutions 1. Discuss about partners 2. Don't obviate discussion about condom use 3. Nurse/staff collaboration

Congratulations! Top recruiters in Spain Dr. Pompeyo Viciana. Hospital Virgen del Rocío, Seville: 39 couples Dr. Félix Gutiérrez Hospital Elche, Alicante: 24 couples



Understanding why serodifferent couples do not always use condoms when the HIV positive partner is on ART

Alison Rodger, Tina Bruun, Pietro Vernazza , Simon Collins, Vicente Estrada, Jan Van Lunzen, Giulio Maria Corbelli, Pompeyo Viciana, Andrew Phillips and Jens Lundgren for the PARTNER Study Group

People do not always use a condom when having sex with partners of neg/unknown HIV status One reason for not using condoms may be the person being ART with the VL< 50 copies/mL and statements on likely reduced infectiousness in this situation have been issued The secondary aim of the PARTNER study is to study HIV serodifferent partnerships to understand why some partnerships do not use condoms and factors associated with this

Design and Methods

- The PARTNER study is an international, observational multi-centre study, taking place in 72 European sites from 2010 to 2014
- Recruits serodifferent partnerships who had CL penetrative sex in the past 4 weeks, +ve partner on ART, to assess risk behaviours, reasons for non-condom use, attitudes to use of ART for prevention, and to estimate the absolute risk of HIV transmission on ART with a viral load <50 copies/mL with 4-6 monthly follow up
- We report baseline risk behavior data on first 565 couples (373 HS and 192 MSM) recruited to 02/02/2012



Results: HIV acquisition route, adherence and VL knowledge					
		HIV+ heterosexual men (n=179)	HIV+ women (n=190)	HIV+ MSM (n=191)	p-value
HIV A	cquisition route				
	Heterosexual Sex	62 (36.3)	115 (66.1)	0(0)	<0.0001
	Homosexual Sex	12 (7.0)	0	168 (96.5)	
	IVDU	62 (36.3)	10(5.7)	0(0)	
Years HIV diagnosis, median (IQR)		12.5 (7.3-19.3)	10.4(6.2-16.4)	6.8(4.3-12.7)	<0.0001
Years	on ART, median (IQR)	9 (4.1-14.7)	7.4 (3.3-13.6)	5.0(1.8-11.3)	<0.0001
Self-reported adherence >=90%		157(92.9)	156 (95.1)	166 (97.0)	0.2079
Missed ART for >4 cons days		9 (5.2)	10 (5.7)	3 (1.7)	0.1072
Informed partner if missed ART		86 (85.1)	84 (88.4)	61 (85.9)	0.7869
Thought had undetectable VL		142 (84.5)	147 (86.0)	163 (95.3)	0.0030
Undetectable VL (<50 copies)		163 (90.1)	180 (95.7)	181 (94.7)	0.0742
CD4 c	ount >350 mm ³	150 (82.9)	167(88.8)	169 (88.8)	0.1669

Results: HIV acquisition route, adherence and VL knowledge

		HIV+	HIV+ women	HIV+ MSM	p-value
		heterosexual	(n=190)	(n=191)	
		men (n=179)			
HIV Acquisition route					
	Heterosexual Sex	62 (36.3)	115 (66.1)	0(0)	<0.0001
	Homosexual Sex	12 (7.0)	0	168 (96.5)	
	IVDU	62 (36.3)	10(5.7)	0(0)	
Years HIV diagnosis, median (IQR)		12.5 (7.3-19.3)	10.4(6.2-16.4)	6.8(4.3-12.7)	<0.0001
Years on ART, median (IQR)		9 (4.1-14.7)	7.4 (3.3-13.6)	5.0(1.8-11.3)	<0.0001
Self-reported adherence >=90%		157(92.9)	156 (95.1)	166 (97.0)	0.2079
Missed ART for >4 cons days		9 (5.2)	10 (5.7)	3 (1.7)	0.1072
Informed partner if missed ART		86 (85.1)	84 (88.4)	61 (85.9)	0.7869
Thought had undetectable VL		142 (84.5)	147 (86.0)	163 (95.3)	0.0030
Undetectable VL (<50 copies)		163 (90.1)	180 (95.7)	181 (94.7)	0.0742
CD4 count >350 mm ³		150 (82.9)	167(88.8)	169 (88.8)	0.1669
					**PARTNER

Results: HIV acquisition route, adherence and VL knowledge


		HIV+ heterosexual men (n=179)	HIV+ women (n=190)	HIV+ MSM (n=191)	p-value
HIV A	acquisition route				
	Heterosexual Sex	62 (36.3)	115 (66.1)	0(0)	<0.0001
	Homosexual Sex	12 (7.0)	0	168 (96.5)	
	IVDU	62 (36.3)	10(5.7)	0(0)	
Years HIV diagnosis, median (IQR)		12.5 (7.3-19.3)	10.4(6.2-16.4)	6.8(4.3-12.7)	<0.0001
Years on ART, median (IQR)		9 (4.1-14.7)	7.4 (3.3-13.6)	5.0(1.8-11.3)	<0.0001
Self-reported adherence >=90%		157(92.9)	156 (95.1)	166 (97.0)	0.2079
Missed ART for >4 cons days		9 (5.2)	10 (5.7)	3 (1.7)	0.1072
Informed partner if missed ART		86 (85.1)	84 (88.4)	61 (85.9)	0.7869
Thought had undetectable VL		142 (84.5)	147 (86.0)	163 (95.3)	0.0030
Undetectable VL (<50 copies)		163 (90.1)	180 (95.7)	181 (94.7)	0.0742
CD4 count >350 mm ³		150 (82.9)	167(88.8)	169 (88.8)	0.1669


Results: HIV acquisition route, adherence and VL knowledge

		HIV+	HIV+ women	HIV+ MSM	p-value
		heterosexual	(n=190)	(n=191)	
		men (n=179)			
HIV A	acquisition route				
	Heterosexual Sex	62 (36.3)	115 (66.1)	0(0)	<0.0001
	Homosexual Sex	12 (7.0)	0	168 (96.5)	
	IVDU	62 (36.3)	10(5.7)	0(0)	
Years HIV diagnosis, median (IQR)		12.5 (7.3-19.3)	10.4(6.2-16.4)	6.8(4.3-12.7)	<0.0001
Years on ART, median (IQR)		9 (4.1-14.7)	7.4 (3.3-13.6)	5.0(1.8-11.3)	<0.0001
Self-reported adherence >=90%		157(92.9)	156 (95.1)	166 (97.0)	0.2079
Missed ART for >4 cons days		9 (5.2)	10 (5.7)	3 (1.7)	0.1072
Informed partner if missed ART		86 (85.1)	84 (88.4)	61 (85.9)	0.7869
Thought had undetectable VL		142 (84.5)	147 (86.0)	163 (95.3)	0.0030
Undetectable VL (<50 copies)		163 (90.1)	180 (95.7)	181 (94.7)	0.0742
CD4 count >350 mm ³		150 (82.9)	167(88.8)	169 (88.8)	0.1669

Results: HIV acquisition route, adherence and VL knowledge

		HIV+	HIV+ women	HIV+ MSM	p-value
		heterosexual	(n=190)	(n=191)	
		men (n=179)			
HIV A	Acquisition route				
	Heterosexual Sex	62 (36.3)	115 (66.1)	0(0)	<0.0001
	Homosexual Sex	12 (7.0)	0	168 (96.5)	
	IVDU	62 (36.3)	10(5.7)	0(0)	
Years HIV diagnosis, median (IQR)		12.5 (7.3-19.3)	10.4(6.2-16.4)	6.8(4.3-12.7)	<0.0001
Years on ART, median (IQR)		9 (4.1-14.7)	7.4 (3.3-13.6)	5.0(1.8-11.3)	<0.0001
Self-r	reported adherence >=90%	157(92.9)	156 (95.1)	166 (97.0)	0.2079
Miss	ed ART for >4 cons days	9 (5.2)	10 (5.7)	3 (1.7)	0.1072
Infor	med partner if missed ART	86 (85.1)	84 (88.4)	61 (85.9)	0.7869
Thought had undetectable VL		142 (84.5)	147 (86.0)	163 (95.3)	0.0030
Undetectable VL (<50 copies)		163 (90.1)	180 (95.7)	181 (94.7)	0.0742
CD4 count >350 mm ³		150 (82.9)	167(88.8)	169 (88.8)	0.1669






Reasons given for not using a condom

The main reasons given for not using a condom:

- A belief that the risk of transmission was low (52% +ve, 54% -ve)
- HIV –ve partner did not want to use a condom (48% HS, 27% MSM)
- Trying for a pregnancy (43% HS)
- Didn't think about it (21% MSM and 30% HS)
- Greater pleasure without a condom (46% +ve, 47% -ve)



PARTNE



Conclusions

- In MSM we found the HIV positive partner was more likely to be anal receptive and, if insertive, avoided ejaculation
- A significant proportion of HS HIV –ve women had anal sex with ejaculation with their HIV +ve male partners.
- The decision not to use condoms in HS men was significantly related to a belief that condoms are not necessary when VL is undetectable.
- Results from the HPTN 052 trial and growing awareness of the prevention role of ART, are likely to increase this belief.
- Accurately defining the actual risks for condomless sex, both anal and vaginal, with the use of ART will be critical to defining the safety or risk of these choices

Ref: Cohen MS, et al for the HPTN 052 Study Team. NEJM 2011



PARTNER

Cour		required: 250		llow-up per year
Recru	uitment nonth	% ending follow-up per year	<u>o</u> Cumulative recruitment by Feb 2014	Total follow- to Aug 2014
30		15%	1256	2244
30		20%	1256	2131
30		25%	1256	2021
40	15%	1476	2562	
40		20%	1476	2434
40		25%	1476	2309

recruitmen MSM			to monthly llow-up peryear
Recruitment per month until Feb 2014	% ending follow-up per year	Cumulative recruitment by Feb 2014	Total follow- to Aug 2014
13	15%	486	850
13	20%	486	807
13	25%	486	766
30	15%	860	1390
30	20%	860	1322
30	25%	860	1255
			Partner

Guidelines: Emphasize the 6 month visits Explain the reasons for the 6-month HIV test Schedule dates for follow-up visits at the baseline visit Rapid testing – this can minimize the number of visits for the HIV negative partner If the HIV negative partner refuses to continue to participate in the study an exception can be made and they are allowed to come in for testing only once a year. In such cases it is important to have the HIV negative partner fill in follow up questionnaires every 6 months.

Follow up



Why a Community Lead for the Partner study?

- The Partner Study is important for the community
- Reaching sero-different couples for recruitment can be not easy
- The community lead can be a trait-d'union between researcher and the community
- Cooperation is useful and necessary



Community Lead for the Partner study - 2012

- Italy: Giulio Maria Corbelli
- Spain: Michael Meulbroek
- Finland: Kimmo Karsikas
- Switzerland: David Haerry
- Portugal: Wim Vandevelde
- UK: Simon Collins
- Austria: Frank Michael Amort
- France: Laurent Rossignol
- Denmark: Klaus Legau
- Belgium: Koen Block?
- Germany: Dirk SandersSweden: Helena Granlund

No Community Lead:

The Netherlands: Decided not to appoint



